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Abstract
Background: The antitumor drug daunorubicin exerts some of its cytotoxic effects by binding to
DNA and inhibiting the transcription of different genes. We analysed this effect in vivo 
transcriptome level using the budding yeast Saccharomyces cerevisiae as a model and sublethal (IC40)
concentrations of the drug to minimise general toxic effects.
Results: Daunorubicin affected a minor proportion (14%) of the yeast transcriptome, increasing
the expression of 195 genes and reducing expression of 280 genes. Daunorubicin down-regulated
genes included essentially all genes involved in the glycolytic pathway, the tricarboxylic acid cycle
and alcohol metabolism, whereas transcription of ribosomal protein genes was not affected or even
slightly increased. This pattern is consistent with a specific inhibition of glucose usage in treated
cells, with only minor effects on proliferation or other basic cell functions. Analysis of promoters
of down-regulated genes showed that they belong to a limited number of transcriptional regulatory
units (regulons). Consistently, data mining showed that daunorubicin-induced changes in
expression patterns were similar to those observed in yeast strains deleted for some transcription
factors functionally related to the glycolysis and/or the cAMP regulatory pathway, which appeared
to be particularly sensitive to daunorubicin.
Conclusion: The effects of daunorubicin treatment on the yeast transcriptome are consistent
with a model in which this drug impairs binding of different transcription factors by competing for
their DNA binding sequences, therefore limiting their effectiveness and affecting the corresponding
regulatory networks. This proposed mechanism might have broad therapeutic implications against
cancer cells growing under hypoxic conditions.
Background
Understanding the mode of action of antitumor drugs is
considered an absolute prerequisite for the advancement
on the design of new drugs. It is generally believed that
antitumor activity is mediated by the capacity of certain
drugs to induce DNA damage and trigger apoptosis. How-
ever, there are many indications that this mechanism,
whatever relevant may it be, does not account for all ther-
apeutic effects of some antitumor drugs [1,2].
The anthracycline antibiotic daunorubicin is widely used
in cancer chemotherapy [3]. It accumulates in the nuclei
of living cells and intercalates into DNA quantitatively
[4,5], a property associated to some of the most relevant
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effects of the drug: inhibition of DNA replication and gene
transcription [1,6,7], displacement of protein factors from
the transcription complex [8] and topoisomerase II poi-
soning [9]. Daunorubicin has the property of arresting cell
growth at drug concentrations not sufficient for promot-
ing noticeable DNA damage, and through mechanisms
that differ from the apoptotic pathway [7]. These findings
impelled to define new mechanisms of daunorubicin
antiproliferative activity at clinically relevant concentra-
tions.
Daunorubicin shows remarkable sequence specificity for
5'-WCG-3' DNA tracts [10]. This property has led to the
suggestion that daunorubicin may compete with tran-
scription factors with overlapping recognition sites for
binding to DNA. This model would explain several effects
of daunorubicin, such as inhibition of RNA polymerase II
[1,6,7] and the suppression of the co-ordinate initiation
of DNA replication in Xenopus oocyte extracts [11].
To test the capacity of daunorubicin to displace key tran-
scription factors from their binding sites in chromatin in
vivo, and, therefore, to inhibit their action [6], we used the
yeast Saccharomyces cerevisiae as a model. In a previous
work [12], we showed that yeast strains deficient in ergos-
terol synthesis (Δerg6 strains) are particularly sensitive to
daunorubicin, overcoming one of the main setbacks to
the use of yeast in pharmacological studies, which is their
resistance to many anti-tumour drugs [13,14].
We demonstrated that daunorubicin treatment in Δerg6
cells precluded activation of several genes required for
galactose utilization (GAL genes) and, consequently,
treated cells were unable to growth in galactose. This effect
was related to the presence of CpG steps in the cognate
DNA binding sequence of Gal4p, the key transcription
factor for activation of GAL genes [12,15]. The present
work aims to extend this type of analysis to the totality of
the yeast genome, in order to assess the generality of this
model.
Results
Effects of daunorubicin on the yeast transcriptome
The effects of daunorubicin on the yeast transcriptome
were studied after 1 h and 4 h of treatment (Figure 1). The
results indicate a general inhibitory effect of daunorubicin
at both time points, as down regulated genes predominate
over up regulated ones, and this trend was especially sig-
nificant when considering genes whose expression
changed by more than four-fold (lines "4X" and "0.25X"
in Figure 1). Multi-array analysis of the expression
changes in the whole dataset confirmed these trends.
ANOVA analysis of normalized data showed statistically
significant differences in expression upon daunorubicin
treatment for 475 genes (14%) at least in one of the time
points analysed. Affected genes were grouped in four clus-
ters by a Self-Organising Maps (SOM) algorithm, accord-
ing to their differential expression at the three time points
analysed (Figure 2, list of genes for each cluster in Table
1). Clusters A to C (280 genes in total) corresponded to
genes whose transcription decreased upon daunorubicin
treatment, whereas all genes that became activated by the
treatment (195 genes) were grouped in Cluster D. Genes
in Clusters C and D showed very little or no difference in
expression between one and four hours of treatment (see
the horizontal median line in the corresponding plots
between time points 1 h and 4 h in Figure 2), whereas
genes in Cluster A were the only ones in which the effect
(an inhibition, in this case) after four hours of treatment
was significantly stronger than the observed after one
hour (Figure 2). Cluster B, consisting only in three genes,
was the only one in which the effect was stronger at one
hour than at four hours. Our data thus indicated that most
daunorubicin-related changes in gene expression were
already significant after only one hour of treatment and
that these effects either increased or remained stable after
four hours for essentially all analysed genes.
Gene Ontology (GO) analysis of genes activated and
repressed by daunorubicin treatment showed a very differ-
ent distribution of GO categories for both groups. Up-reg-
ulated genes fell into three main functional categories:
Genes related to ribosome assembly and metabolism, Ty
transposition, and proteolytic processes (Table 2).
Whereas the two last categories may indicate a certain
level of stress, up regulation of ribosome assembling-
related genes usually correlates with a positive effect in
cell growth. In contrast, GO analysis of genes down regu-
lated by daunorubicin showed a general decrease of
energy-producing metabolism, including genes involved
in fermentation and in the tricarboxylic acid cycle. A sig-
nificant proportion of down-regulated genes appeared
involved in the metabolism of nitrogen compounds,
including amino acids (Table 3). The dissociation
between expression of ribosomal and glycolytic genes
upon daunorubicin treatment can be observed in Figure 3,
which shows up-regulation of most ribosomal protein
genes and down-regulation of sugar and alcohol-metabo-
lism related genes at one and four hours of daunorubicin
treatment. Figure 4 shows a scheme of the glycolytic path-
way, highlighting genes down regulated by daunorubicin.
These genes codify the enzymes responsible for no less
than 9 consecutive steps of the pathway. Therefore, the
data suggests that the fermentation capacity should be
depressed in daunorubicin-treated yeast cells.
The effects of daunorubicin treatment in gene expression
of 15 selected genes were validated by qRT-PCR (list of
genes and primers in Table 4, results in Table 5). The
results, presented as ratios between treated and untreatedBMC Genomics 2008, 9:358 http://www.biomedcentral.com/1471-2164/9/358
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Table 1: Gene clusters defined by SOM analysis
Cluster A Cluster B Cluster C Cluster D
AAH1 GPI12 PPM1 YDR428C URA2 ACT1 ACC1 RPC31 YBL051C YMR074C
AAT2 GPM1 PRB1 YDR453C YJU3 ARG8 ANB1 RPC40 YBL057C YMR085W
ACO1 GPM2 PRY1 YDR516C YML056C ARO4 ARL1 RPG1 YBR012W-B YMR130W
ADE12 GRE2 PRY3 YDR539W AYR1 BFR1 RPL13B YCL019W YMR158C-B
ADE17 GRE3 PSA1 YFR017C CAR2 CAF20 RPL32 YCR082W YNL054W-B
ADH1 GSF2 PST1 YGL121C CDC91 CBF5 RPL34B YDL076C YNL296W
ADH2 GSY2 RAD51 YGL157W DAK1 CCT5 RPL6A YDL157C YNR046W
ADH5 GTT1 RHR2 YGP1 ERG10 CDC20 RPL6B YDL166C YOL026C
ALD4 GYP7 RIB1 YGR045C FAS1 CDC33 RPN10 YDR034C-D YOL092W
ALD6 HHO1 RIB4 YGR161C GDH1 CDC60 RPO26 YDR060W YOL124C
AMS1 HMT1 RIP1 YHL021C GLT1 COP1 RPS11B YDR084C YOR021C
ARA1 HOR2 RME1 YHM1 NUP82 CPR6 RPS19A YDR098C-B YOR262W
ARG1 HSP104 RNR1 YHR087W PFK1 DIB1 RPS26A YDR154C YOR343C-A
ARG4 HSP12 SCM4 YIL011W PHB1 DPB4 RPS4B YDR210C-D YOR343C-B
ARG5 HSP26 SCS7 YIL056W PYC2 DST1 RPS8A YDR210W-D YOR382W
ARO3 HSP42 SCW11 YIL077C QCR10 FCY1 RPT3 YDR261C-D YPL199C
ASH1 HXK1 SDS24 YJL016W QCR2 FKB2 RRP4 YDR261W-B YPL225W
BAP2 HXK2 SGE1 YJL094C RFC5 FPR1 RRP5 YDR316W-B YPR137C-B
BAP3 HXT1 SHM2 YJR008W RNR4 FRQ1 RRP9 YDR361C YPR158W-B
BAT2 HXT2 SNO1 YKL151C STI1 HCH1 RRS1 YDR365W-B YPS7
CAP2 IDH1 SNQ2 YKR067W STP3 HIR1 RSC6 YDR449C YPT31
CBP4 IDH2 SNZ1 YLL012W TEF1 HIS7 RVB2 YER007C-A
CHA1 ILV5 SPI1 YLR110C TKL1 HRP1 SAS10 YER092W
CHS1 INO1 SRL3 YLR111W TSA1 HRR25 SBH1 YER126C
CIT1 IPT1 SRY1 YLR122C TTR1 HRT1 SEC21 YER138C
CLN2 IRA2 SSA1 YLR231C UGA1 ILS1 SEC65 YER160C
COQ1 KNS1 SSA2 YLR331C URA4 IMP4 SEC72 YER183C
COS1 LAP4 SSD1 YLR352W YBR070C KAP123 SER3 YFH1
COS7 LSC2 SUN4 YLR414C YDR214W KRI1 SES1 YFL002W-A
COX20 MCR1 TAT2 YLR454W YDR476C KRR1 SIT1 YFL004W
CPA1 MDH1 TDH1 YML128C YER134C LOS1 SKP1 YGR038C-B
CTS1 MDH2 TDH2 YMR090W YER182W LYS7 SMD3 YGR081C
CYC3 MEP1 TDH3 YMR173W-A YGL047W MGM101 SNF8 YGR161W-B
CYT1 MEP3 THO1 YMR181C YGR201C NAT3 SNT309 YHR052W
DDR2 MET6 TIR2 YMR315W YHR049W NIP7 SPB1 YHR214C-B
DDR48 MMD1 TPI1 YNL200C YIL087C NMD3 SPE3 YHR214C-C
DED1 MOG1 TPS2 YNL212W YIR035C NOP12 SPE4 YIL127C
DYN1 MRPL35 TRR2 YOL101C YLL023C NOP58 SSF1 YJR027W
EHT1 MSF1' TSL1 YOR009W YLR112W NPI46 SSP120 YJR029W
ENO1 MTF2 TUF1 YOR022C YLR356W NPT1 STS1 YKL014C
ENO2 NCE102 UGP1 YOR062C YMR178W NRD1 SUI1 YKL054C
ERG11 NCR1 URA1 YOR081C YNL100W OLI1 SUI2 YKR081C
ERG26 OAC1 UTR2 YOR258W YNL305C OST3 SXM1 YKT6
ERG5 OPI3 VAP1 YOR280C YPL101W PCL1 TIF11 YLR009W
ERG6 PBI2 VID24 YOR289W YPR098C PFS2 TIF34 YLR035C-A
EXG1 PCL7 YAL053W YOR338W YSA1 PHO11 TIF35 YLR065C
FBA1 PDC1 YBL049W YPL004C PHO12 TIP1 YLR106C
FUN14 PDC5 YBL064C YPL066W PRE10 TPM1 YLR157C-B
GCV1 PDH1 YBR006W YPL134C PRE2 TPM2 YLR159W
GCV2 PDR5 YBR053C YPL156C PRE3 TRP1 YLR221C
GCY1 PET8 YBR230C YPR153W PRE9 UBA1 YLR227W-B
GLK1 PEX11 YDC1 YPR172W PUP2 UBC1 YLR410W-B
GLO1 PGK1 YDL124W YRA1 RDI1 UBC13 YML039W
GLY1 PGM2 YDR041W YTP1 RLP7 UBC4 YML093W
GND1 PHO3 YDR233C ZRT1 RNA14 UBC6 YML125C
GPA2 PIR1 YDR319C ZRT2 RNH70 URA5 YMR045C
GPD2 PLB1 YDR387C RPA49 VAR1 YMR046W-A
GPH1 PPA2 YDR391C RPC10 YBL005W-B YMR050CBMC Genomics 2008, 9:358 http://www.biomedcentral.com/1471-2164/9/358
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cells at 0 h and 4 h of treatment, include data from up to
5 biological replicates, showed a general good agreement
with microarray data. Most (8 out of 9) sugar and alcohol-
metabolism related genes showed a 2 to 4 fold decrease
on expression of after 4 h of treatment, a behaviour com-
parable to the one observed in the microarray analysis.
Similarly, two out of the three amino acid metabolism
genes analysed showed a 3 to 4 fold decrease on expres-
sion. In contrast, a small, but significant, increase on the
expression of the ribosomal protein genes RPS28A was
also observed, also in agreement with the general trend
observed for ribosomal-protein genes in the microarray
data. We added to this analysis the heat-shock protein
HSP26, as a representative of a small group of HSP genes
(HSP12, HSP26, HSP42 and HSP104) with appeared
down regulated by daunorubicin in the microarray analy-
sis (Table 1). These results were corroborated by qRT-PCR
quantitation, which showed 8-fold reduction of HSP26
transcription after four hours of daunorubicin treatment
(Table 5). These results confirmed the general decrease in
genes related with glucose utilisation while transcription
of ribosomal protein gene was either not affected or
slightly increased.
Identification of transcription factors associated to 
daunorubicin-repressed genes
Transcription factors reported to bind to the promoters of
daunorubicin-repressed genes were identified using the
on-line bioinformatics tools available at the YEASTRACT
web page (http://www.yeastract.com/, [16]). From the
170 transcription factors included in the YEASTRACT
database, 32 of them were found to bind to daunorubicin-
repressed gene promoters in a significantly higher propor-
tion than expected only by chance (Table 6). The table
indicates the total number of genes associated to each
transcription factor present in the whole dataset (that is,
the 3458 ORF analysed), the number of these genes show-
ing down-regulation by daunorubicin, the expected
Effects of daunorubicin to the yeast transcriptome Figure 1
Effects of daunorubicin to the yeast transcriptome. Expression data from treated and untreated cells (expressed as 
binary logs) were compared before and after one and four hours of incubation with daunorubicin. Data are represented as log2 
of the ratios of gene expression values after 1 h (left) and 4 h (right) of daunorubicin treatment versus the initial values (Time 
0). Only genes whose expression was significantly altered by the treatment (T-test, brown dots, p < 10-5, yellow squares, p < 
10-2) are shown. Discontinuous lines in the plots indicate the calculated positions of genes changed by 4-, 2-, 0.5- and 0.25-fold; 
they are included as references to compare with the changes in expression of different genes.BMC Genomics 2008, 9:358 http://www.biomedcentral.com/1471-2164/9/358
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number by a random distribution (over 280 down regu-
lated genes) and the "enrichment factor", that is, the ratio
between observed and expected absolute frequencies for
each factor.
Some of these factors (Yap1p, Msn2p, Msn4p) are inti-
mately related to stress response, whereas others, such as
Gcr2p, Adr1p, Mig1p and Rgt1p, are associated to carbo-
hydrate and alcohol metabolism. In addition, Gcn4p and
Met4p are known regulators of amino acids biosynthetic
pathways. In this regard, the transcription factor list reca-
pitulates the functional distribution of daunorubicin
down regulated genes in Table 3. Fourteen transcription
factors showed enrichment factors over 3 fold, indicating
that their associated genes were found in the daunoru-
bicin down regulated dataset at 3 to 5 times higher fre-
quencies than expected (Table 7). Many of these factors
are known regulators of glycolytic genes, such as Rgt1p,
Mig1p, Gcr2p or Adr1p; therefore, their inclusion in the
list may merely reflect the general decrease of transcrip-
tion of the regulated genes. In addition, this list includes
a strikingly high proportion (10 out 14) of transcription
factors encompassing CpG steps in their DNA binding
sites, irrespectively their relationship with the glycolytic
pathway. This observation is consistent with a preferential
effect of daunorubicin on the expression of genes regu-
lated by transcription factors with CpG steps in their DNA
recognition sequences, in keeping with previous results
[8]. This specific inhibition of transcriptional activation
by daunorubicin suggests that it may compete with some
transcription factors for DNA binding in CpG-reach
sequences in gene promoters.
Correlation of daunorubicin effects and deletions of 
transcription factor genes
A direct prediction of the DNA-binding competition
model for daunorubicin action is that its presence in the
cell should produce a phenocopy of genetic deletion of
these factors [12], or their partial depletion [7]. To test this
prediction, we compared the effects of daunorubicin
shown here with a large dataset of null deletions of 42
transcription factors, many of them coincident with the
set in Table 6[17]. Table 8 shows the correlation between
microarray data from six deletion strains [17] and the cor-
responding figures from the 4 h daunorubicin-treatment
dataset. For these calculations, ratios between deleted and
wild type strains were compared to 4 h to 0 h ratios, only
for those genes that showed significant variations in
expression (positive or negative) due to daunorubicin
treatment. The six strains shown in Table 8 are the only
ones in the dataset [17] showing positive and significant
correlation (p < 0.001, Bonferroni) with daunorubicin-
Transcriptional profiles for genes classified into clusters by SOM Figure 2
Transcriptional profiles for genes classified into clusters by SOM. Data are shown as logarithmic values of the ratio of 
fluorescence between treated and untreated cells before (0 h) and 1 and 4 hours after treatment. No correction was per-
formed to compensate differences in labelling or detection of the two fluorochromes. The thick solid lines in the middle of the 
graphs correspond to median values, coloured areas correspond to the intervals between 1st and 3rd quartiles (dark gray) and 
the total distribution (light gray). Averaged values for Cluster B (3 genes, discontinuous line) in included in the Cluster A plot.BMC Genomics 2008, 9:358 http://www.biomedcentral.com/1471-2164/9/358
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treatment data. The best correlation values corresponded
to three strains deleted for factors Adr1p, Cst6p and
Sok2p; graphs in Figure 5 show expression ratios for these
three strains plotted against the corresponding values
from daunorubicin treatment. These plots strongly sug-
gest that at least part of the changes in transcription ratios
induced by daunorubicin may be due to competition of
the drug with these and other transcription factors for
binding to consensus DNA sequences.
Discussion
The yeast Saccharomyces cerevisiae is a favourite tool for
testing drugs that interact and/or modify gene regulation,
since it shares many common regulatory mechanisms
with vertebrates, ranging from cell cycle to transcriptional
regulation [13,18-20]. In a previous paper [12], we
showed that daunorubicin specifically inhibited genes
required for galactose utilisation, a phenotype we pro-
posed linked to the presence of CpG steps in the recogni-
tion sequence of the main regulator for these genes,
Table 2: GO Term finder results for genes up-regulated by daunorubicin
Gen Ontology Term clustering
Functional categories GOID GOID- associated functions
A 32196; 32197 Transposition, Ty metabolism
B 27; 460; 466; 6364; 6396; 6996; 16043; 
16070; 16072; 22613; 22618; 42254; 
42255; 42257; 42273; 43170; 65003
Ribosome assembling (Protein and 
rRNA) Proteolysis. Ubiquitin-
C 6508; 6511; 19941; 30163; 43632; 44257; 
51603
mediated preoteolysis.
Gene Clustering
Distribution among functional categories Genes Main gene functions Number of genes
A only FCY1; FRQ1; HIS7; PCL1; PHO11; SER3; 
SIT1; SPE3; SPE4; TRP1; URA5; 
YBL005W-B; YBR012W-B; YCL019W; 
YDR034C-D; YDR098C-B; YDR210C-
D; YDR261C-D; YDR261W-B; 
YDR316W-B; YDR365W-B; YER138C; 
YER160C; YFL002W-A; YGR038C-B; 
YGR161W-B; YHR214C-B; YHR214C-
C; YJR027W; YJR029W; YLR035C A; 
YLR157C-B; YLR227W-B; YLR410W-B; 
YML039W; YMR045C; YMR050C; 
YNL054W-B; YPR137C-B; YPR158W-B
Ty genes 40
B only ACC1; ANB1; ARL1; BFR1; CAF20; 
CBF5; CCT5; CDC33; CDC60; COP1; 
CPR6; DIB1; DPB4; DST1; FPR1; HCH1; 
HIR1; HRP1; HRR25; ILS1; IMP4; 
KAP123; KRI1; KRR1; LOS1; MGM101; 
NAT3; NIP7; NMD3; NOP12; NOP58; 
NPT1; NRD1; OST3; PFS2; RDI1; RLP7; 
RNA14; RNH70; RPA49; RPC10; 
RPC31; RPC40; RPG1; RPL13B; RPL32; 
RPL34B; RPL6A; RPL6B; RPO26; 
RPS11B; RPS19A; RPS26A; RPS4B; 
RPS8A; RRP4; RRP5; RRP9; RRS1; RSC6; 
RVB2; SAS10; SEC21; SEC65; SEC72; 
SES1; SMD3; SNT309; SPB1; SSF1; 
SSP120; SUI1; SUI2; SXM1; TIF11; TIF34; 
TIF35; TIP1; TPM1; TPM2; UBA1; 
UBC13; YFH1; YIL127C; YKT6; 
YNL296W; YOR021C; YPT31
Ribosomal protein genes, rRNA 
metabolism, translation.
87
C>B CDC20; HRT1; PRE10; PRE2; PRE3; 
PRE9; PUP2; RPN10; RPT3; SKP1; SNF8; 
STS1; UBC1; UBC4; UBC6
Endopeptidases, ubiquitin-protein ligases 15
No GO Term 53BMC Genomics 2008, 9:358 http://www.biomedcentral.com/1471-2164/9/358
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Gal4p. Here we extended these studies to the whole yeast
transcriptome, in conditions of mild inhibition of cell
growth.
Daunorubicin treatment affected transcription of a rela-
tive small proportion of genes. We chose a relatively mild
treatment, slightly under the IC50, in order to minimise
general toxic effects in cell membranes and widespread
DNA damage. A conclusion from our analysis is the selec-
tive repression by daunorubicin of genes involved in the
glycolytic pathway, whereas other genes involved in
growth, like ribosomal protein genes, were either not
affected or slightly activated. This pattern is very rarely
observed in yeast, as glucose utilisation is required for fast
growth. Figure 6 shows ratios of expression changes for 32
glycolysis-related genes (gly genes) and 123 ribosomal
protein genes (rpg genes) in 146 stress conditions, includ-
ing DNA damage (both chemical and by irradiation), oxi-
dative and osmotic stress, amino acid and nitrogen
starvation, entering in stationary phase, and temperature
shifts ([21,22]; list of genes and conditions in Table 9).
The graph shows both the ratio between both sets of genes
and p-values associated to their differential response to
each stress. Low p-values (upper part of the graph, note
the reversed Y-axis) correspond to data sets in which the
response of both sets of genes showed little or no overlap,
whereas high p-values (lower part of the graph) implicate
that both sets of genes responded similarly to that specific
stress condition. The graph shows that ribosomal protein
genes are preferentially inhibited in many stress condi-
tions compared to glycolysis-related genes (right portion
of the graph), whereas daunorubicin treatment datasets (1
Table 3: GO Term finder results for genes down-regulated by daunorubicin
Gen Ontology Term clustering
Functional categories GOID GOID- associated functions
A 5975; 5996; 6006; 6007; 6066; 6067; 
6082; 6090; 6094; 6096; 6113; 6766; 
6767; 9056; 9063; 15980; 16051; 16052; 
19318; 19319; 19320; 19752; 32787; 
44248; 44262; 44275; 46164; 46165; 
46364; 46365;
Alcohol and carbohydrate metabolism 
(including glycolysis). Vitamin and 
organic acid metabolism.
B 6091; 6099; 6100; 6519; 6520; 6536; 
6537; 6807; 8652; 9064; 9084; 9308; 
9309; 44271; 46356
Amino acid metabolic process. 
Tricarboxilic acid cycle.
Gene Clustering
Distribution among functional categories Genes Main gene functions Number of genes
A>>B GPD2; PDC1; PDC5; PCL7; UGP1; 
DAK1; GLO1; INO1; PGM2; MDH2; 
PSA1; GRE3; GCY1; GLK1; TPI1; HXK1; 
HXK2; PFK1; VID24; GND1; TKL1; 
PYC2; PGK1; TDH3; ENO1; ENO2; 
TDH1; TDH2; FBA1; GPM1
Glycolysis 30
A>B AAH1; ADH1; ADH2; ADH5; ALD4; 
ALD6; AMS1; ARA1; AYR1; CTS1; 
EHT1; ERG10; ERG11; ERG26; ERG5; 
EXG1; FAS1; GPH1; GSY2; HOR2; 
LAP4; MDH1; PDH1; PEX11; PHO3; 
PRB1; RHR2; RIB1; RIB4; SCS7; SNO1; 
SNZ1; TPS2; TSL1
Alcohol, lipid and sterol metabolism 34
A ≈ B AAT2; BAT2; CAR2; CHA1; COX20; 
GCV1; GCV2; GLY1; LSC2; MCR1; 
PPA2; QCR10; QCR2; RIP1; SRY1; 
UGA1
Amino acid metabolism. Respiration 16
A<B ACO1; ARG1; ARG4; ARG8; ARO3; 
ARO4; CIT1; CPA1; CYT1; GDH1; 
GLT1; IDH1; IDH2; ILV5; MEP1; MEP3; 
MET6; URA2
Nitrogen compound (including amino 
acids) metabolism. Tricarboxilic acid 
cylce
18
No GO term 181BMC Genomics 2008, 9:358 http://www.biomedcentral.com/1471-2164/9/358
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h and 4 h) differentiate clearly from the rest by specifically
depressing glycolytic gene transcription without a parallel
decrease of ribosomal synthesis (upper left part of the
graph). We concluded that daunorubicin effects couldn't
be ascribed to any of the tested stresses, including DNA
damage and oxidative stress. This conclusion is further
supported by the fact that many stress-related genes, like
HSPs, were down regulated, rather than up regulated
upon daunorubicin treatment.
Inspection of promoters of daunorubicin-inhibited genes
showed that they present a significant high proportion of
DNA binding sites for a defined subset of transcription
factors, most of them related to sugar metabolism. These
data have to be interpreted not necessarily as an indica-
tion of direct interaction of the drug with these transcrip-
tion factors, but only as a hint of the regulatory networks,
or regulons, particularly affected by the drug. Due to the
complexity of eukaryotic promoters, several factors may
appear in any particular affected promoter, although the
putative direct effect of the drug may affect to only one or
two of them. A particularly relevant example is Mig1p, a
transcriptional repressor central in the catabolite repres-
sion by glucose and that binds to many glycolytic gene
promoters [23]. Therefore, it appears on the lists of tran-
scription factors preferentially associated to daunoru-
bicin-inhibited genes (Tables 6 and 7), although the
hypothetical suppression of its binding to DNA would
result in activation, rather than inhibition, of the affected
gene. This is the most reasonable explanation by the
Transcriptional rate changes for Ribosomal Protein genes  (solid dots) and Glycolytic genes (diamonds) after 1 (Y-axis)  and 4 h (X-axis) of daunorubicin treatment Figure 3
Transcriptional rate changes for Ribosomal Protein 
genes (solid dots) and Glycolytic genes (diamonds) 
after 1 (Y-axis) and 4 h (X-axis) of daunorubicin 
treatment. Data are expressed as logarithmic values of 
expression ratios between treated and untreated cells.
Scheme of the glycolytic pathway Figure 4
Scheme of the glycolytic pathway. Genes codifying for 
the enzymes implicated in each step are detailed; green labels 
indicate genes whose expression was reduced upon dauno-
rubicin treatment.BMC Genomics 2008, 9:358 http://www.biomedcentral.com/1471-2164/9/358
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appearance in these lists of some transcription factors that
do not encompass daunorubicin-preferred sites in their
recognition sequences (Table 7).
Data mining identified several microarray datasets with
patterns resembling to the ones observed in daunoru-
bicin-treated cells. Best correlations were observed for
strains deleted for some glucose-related transcription fac-
tor genes, especially ADR1, CST6 and SOK2. Deletion of
these genes results in a general decrease on transcription
of glycolytic genes with relatively mild effects on tran-
scription of genes related to cell growth, like ribosomal
protein genes -exactly the pattern observed in daunoru-
bicin-treated cells. Two of these three factors (Adr1p and
Cst6p) were identified as preferentially associated to
genes down regulated by daunorubicin (Table 6, Figure
4). This list also includes a high proportion of factors
whose DNA recognition sequences include CpG steps, the
preferred binding site for daunorubicin [4]. Therefore, we
concluded that daunorubicin inhibition of yeast growth
might be mediated by its interaction with DNA at
sequences also recognized by some transcription factors,
resulting in a transcriptional repression of glycolytic
genes, among others. These results corroborate the inter-
est in using yeast mutants as an in vivo system to identify
the determinants of chemosensitivity [13].
The amazing conservation of regulatory elements among
opisthokonta (taxon that includes fungi and animals,
among other groups) allows identification of pathways
and transcription factors common to yeast and humans.
For example, Cst6p is a basic leucine zipper transcription
factor of the ATF/CREB family, which includes bona fide
orthologues in mammals, not only in functional terms
(targets for the cAMP regulatory pathway), but also by
their binding to identical DNA sequences, 5'-TGACGTCA-
Table 4: Primers used in this study
GENE Primer Sequence Function
ACO1 for: 5'-GTGGTGCTGATGCCGTTG-3' Aconitase
rev: 5'-CCTTCAATTCCCATGGACGA-3'
ACT1 for: 5'-TGTGTAAAGCCGGTTTTGCC-3' Actin
rev: 5'-TTGACCCATACCGACCATGAT-3'
ARG1 for: 5'-GCCCACATTTCTTACGAGGC-3' Arginosuccinate synthetase
rev: 5'-TGGTCCGGAGCATCCATT-3'
ARG4 for: 5'-AAATTTGTCCGTCATCCAAACG-3' Argininosuccinate lyase
rev: 5'-CCGGTGTGGACTTTACCAGC-3'
CAR2 for: 5'-CATCGCCCAATTGAAAGCTC-3' L-ornithine transaminase
rev: 5'-CCTTGGATGGGTCGATTACG-3'
CDC19 for: 5'-TGGCCATTGCTTTGGACAC-3' Pyruvate kinase
rev: 5'-GGTGAAGATCATTTCGTGGTTTG-3'
FBA1 for: 5'-AATGCTTCCATCAAGGGTGC-3' Fructose 1,6-bisphosphate aldolase
rev: 5'-CAACTGGGATACCGTAAGCTG-3'
GPM1 for: 5'-TCACCGGTTGGGTTGATGTTA-3' Glycerate Phosphomutase
rev: 5'-TCCTTCAACAATTCACCGGC-3'
HSP26 for: 5'-AGAGGCTACGCACCAAGACG-3' Heat Shock Protein
rev: 5'-AGAATCCTTTGCGGGTGTGT-3'
HXK1 for: 5'-GTTGACAGCGAGACCTTGAGAA-3' Hexokinase isoenzyme 1
rev: 5'-CAACCGGGAATCATTGGAAT-3'
PGI1 for: 5'-CTCAAAGAACTTGGTCAACGAT-3' Phosphoglucoisomerase
rev: 5'-CAAACCGGTGACGTTAGCCT-3'
PGK1 for: 5'-CCCAGGTTCCGTTCTTTTGTTG-3' 3-phosphoglycerate kinase
rev: 5'-TTGACCATCGACCTTTCTGGA-3'
RPO21 for: 5'-AGGTTTGCTGCAATTTGGACTT-3' RNA polymerase II largest subunit B220
rev: 5'-CAACCTCCCCTTGATACGAGC-3'
RPS28A for: 5'-AGCCAAGGTCATCAAAGTTTTAGG-3' Ribosomal Protein of the Small subunit
rev: 5'-TTCCAAGAATTCGACACGGAC
TDH(1-3) for: 5'-AGACTGTTGACGGTCCATCCC-3' Glyceraldehyde-3-phosphate dehydrogenase
rev: 5'-AAGCGGTTCTACCACCTCTCC-3'
HOR2 for: 5'-GTGCAACGCTTTGAACGCT-3' Glicerol-1-phosphatase
rev: 5'-GAAGTTGCCACAGCCCATTT-3'
TPS2 for: 5'-TCATGCCCCATGGCCTAGTA-3' Trehalose-6-phosphate phosphatase
rev: 5'-TTTCTACGTGGCAAACAACGAA-3'
GLO1 for: 5'-AGGATCCAGCAAGGACCGTT-3' Glyoxalase
rev: 5'-GCTTCATACCGAAGTGTTCGG-3'BMC Genomics 2008, 9:358 http://www.biomedcentral.com/1471-2164/9/358
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3' [24]. This sequence includes a high affinity site for dau-
norubicin, providing an explanation for several of the
effects observed in this work. Sok2p is also known to par-
ticipate in the cAMP regulatory pathway [25], and, there-
fore, many cAMP-regulated promoters encompass
binding sites for both factors. This circumstance provides
a good explanation for the good correlation between the
changes in gene expression due to the deletion of the cor-
responding gene and those observed upon daunorubicin
treatment, although the DNA recognition sequence for
Sok2p (5'-TGCAGNNA-3', [26]) does not include high
affinity sites for daunorubicin. Therefore, our data suggest
that daunorubicin may target the cAMP signalling path-
way of yeast, inhibiting expression of many regulated
genes and particularly those under control of Cst6p, ant
that may be explained by binding of the drug to the Cst6p
DNA recognition site. The question of whether daunoru-
bicin may have similar effects in the cAMP-mediated reg-
ulation of proliferation of mammalian cells is still open.
Extrapolation of these results to tumour cells can be
undertaken at several levels. First, as a general model, they
demonstrate that DNA-intercalating drugs can block cell
growth by selectively reducing the efficiency of different
transcription factors. If these factors are required for cell
growth, this would prevent tumour propagation at effec-
tive concentration of the drug much below the ones
required for the massive DNA damage required to trigger
apoptosis [27,28]. In addition, the specific effects of dau-
norubicin on the glycolysis pathway may be relevant to its
antitumor effect. One of the most outstanding alterations
in cancer cells is their dependence on glycolytic pathways
for the generation of ATP [29], and there is compelling
evidence that mitochondrial defects in tumour cells under
hypoxia are remarkably sensitive to glycolysis inhibition
[29]. Besides, it has been recently reported that some
inhibitors of glucose uptake sensitize tumour cells to dau-
norubicin [30]. Our data would suggest that daunoru-
bicin might work not only as a DNA-damaging agent but
also as an inhibitor of glycolytic pathways, a combined
effect that might have broad therapeutic implications
against cancer cells growing under hypoxic conditions.
Conclusion
The yeast Saccharomyces cerevisiae is a powerful tool for the
study the effects of drugs on eukaryotic cells. We showed
that the antitumor drug daunorubicin alters transcription
of some very specific subsets of genes, in a pattern in
which sugar- metabolising pathways become down-regu-
lated whereas proliferation-related genes, like ribosomal
protein genes, are unaffected or even activated. This pat-
tern is very similar to the one observed in yeast strains
deleted for some transcription factors related to the regu-
lation of the glycolytic pathway, like Adr1p, Cst6p and
Sok2p. This results are consistent with the hypothesis that
daunorubicin impairs binding of different transcription
factors by competing for their DNA binding sequences,
therefore limiting their effectiveness and affecting the cor-
Table 5: Differential expression in daunorubicin-treated versus non-treated cells, measured by RT-qPCR
Treated/Non treateda)
Function ORF Time 0 Time 4 h Fold variation
(4 h/0 h)
pb) Corrected p
(Bonferroni)
n
(technical replicates)
n 
(biological replicates)
ACO1 0.001 -1.090 0.470 0.001 0.020 60 5
CDC19 0.034 -1.132 0.446 6.3 × 10-13 9.5 × 10-12 108 5
FBA1 0.005 -1.207 0.432 1.0 × 10-13 1.5 × 10-12 60 5
GPM1 -0.005 -0.948 0.520 3.0 × 10-8 4.5 × 10-7 60 5
Energy metabolism HOR2 -0.010 -1.413 0.378 9.0 × 10-4 0.014 24 2
HXK1 0.315 -1.935 0.210 1.6 × 10-21 2.5 × 10-20 72 5
PGI1 0.005 -0.061 0.956 0.80 > 0.05 60 5
PGK1 0.005 -1.228 0.425 8.9 × 10-19 1.3 × 10-17 60 5
TDH -0.015 -1.428 0.375 5.9 × 10-12 8.8 × 10-11 60 5
ARG1 -0.010 -2.032 0.246 2.1 × 10-7 3.2 × 10-6 24 2
Amino acid metabolism ARG4 -0.001 -1.413 0.376 5.3 × 10-6 8.0 × 10-5 23 2
CAR2 -0.011 -0.294 0.822 0.09 > 0.05 35 3
ACT1 -0.480 -1.440 0.514 0.126 > 0.05 8 3
Others HSP26 0.081 -2.921 0.125 5.1 × 10-8 7.6 × 10-7 24 2
RPS28A -0.005 0.476 1.396 0.002 0.028 60 5
TPS2 0.002 0.120 1.086 0.42 > 0.05 22 2
a) Data expressed as dual logarithmic values of expression ratios, treated versus untreated. Corrected by RPO21 expression.
b) Student's T-Test, time 0 versus time 4 h ratiosBMC Genomics 2008, 9:358 http://www.biomedcentral.com/1471-2164/9/358
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responding regulatory networks. This proposed mecha-
nism might have broad therapeutic implications in cancer
therapeutics.
Methods
Yeast growth and daunorubicin treatment
Daunorubicin (Sigma, St. Louis, MO, U.S.A.) was freshly
prepared as a 2 mM stock solution in sterile 150 mM NaCl
solution, and diluted to each final concentrations before
use. A single colony of S. cerevisiae (BY4741 erg6Δ (MATa,
his3Δ1, leu2Δ0, met15Δ0, ura3Δ0, YML008c::KanMX4,
from EUROSCARF, Frankfurt, Germany) was inoculated
into 25 ml of YPD medium (10 g/L yeast extract, 20 g/L
peptone and 20 g/L dextrose) and grown overnight at
30°C in an environmental shaker (250 rpm) until expo-
nential phase. This yeast culture was used to inoculate 500
ml of YPD to an initial A600 of 0.1 and further incubated
at the same conditions until A600 = 0.4. This culture was
then divided into three aliquots and diluted four times
with fresh YPD medium. Daunorubicin was then added to
each culture at a final concentration of 12 mM and cul-
tures were allowed to grow for 1 or 4 hours. The whole
procedure was repeated for Real-Time quantitative PCR
(qRT-PCR) validation; in this case, only two biological
replicas were obtained.
RNA Preparation
Cultures were centrifuged for 5 min at 3000 rpm, washed
with 5 ml MilliQ water and subsequently centrifuged
(repeated twice). Total RNA was extracted with the RiboP-
ure Yeast kit (Ambion, Austin, TX, USA). Total RNA was
quantified by spectrophotometry in a NanoDrop ND-
1000 (NanoDrop Technologies, Wilmintong DE, USA)
and its integrity checked on TBE-agarose gels. The result-
ing total RNA was then treated with DNAseI I (F. Hoff-
mann-La Roche, Basel Switzerland) to remove
contaminating genomic DNA.
Table 6: Transcription factors preferently associated to DNR-inhibited genes
Factor Total regulated genesa) DNR-down regulated genes p
Observed Expected (out of 280) Observed/Expected Hypergeometric Bonferroni
Sok2p 561 118 45.45 2.6 5.6 × 10-27 7.2 × 10-25
Msn2p 316 72 25.58 2.8 2.0 × 10-17 2.6 × 10-15
Msn4p 286 67 23.13 2.9 8.3 × 10-17 1.1 × 10-14
Gis1p 91 35 7.35 4.8 1.5 × 10-16 1.9 × 10-14
Cst6p 104 36 8.44 4.3 4.0 × 10-15 5.1 × 10-13
Pdr3p 84 29 6.8 4.3 2.4 × 10-12 3.1 × 10-10
Yap1p 1025 133 83 1.6 2.1 × 10-11 2.8 × 10-9
Met4p 746 105 60.42 1.7 8.8 × 10-11 1.1 × 10-8
Adr1p 148 36 11.97 3.0 3.6 × 10-10 4.6 × 10-8
Xbp1p 84 26 6.8 3.8 5.3 × 10-10 6.9 × 10-8
Rox1p 202 44 16.33 2.7 6.2 × 10-10 7.9 × 10-8
Aft1p 397 66 32.11 2.1 9.5 × 10-10 1.2 × 10-7
Crz1p 155 37 12.52 3.0 1.4 × 10-9 1.8 × 10-7
Pdr1p 205 42 16.6 2.5 3.9 × 10-9 5.1 × 10-7
Skn7p 215 44 17.42 2.5 5.4 × 10-9 7.0 × 10-7
Gcn4p 309 54 25.04 2.2 7.8 × 10-9 1.0 × 10-6
Stp2p 131 32 10.61 3.0 1.5 × 10-8 2.0 × 10-6
Hsf1p 266 48 21.5 2.2 5.2 × 10-8 6.7 × 10-6
Mig1p 74 21 5.99 3.5 1.1 × 10-7 1.4 × 10-5
Ino2p 81 22 6.53 3.4 1.2 × 10-7 1.6 × 10-5
Gcr2p 97 25 7.89 3.2 2.8 × 10-7 3.6 × 10-5
Mga1p 151 31 12.25 2.5 4.6 × 10-7 5.9 × 10-5
Mbp1p 242 42 19.59 2.1 4.6 × 10-7 5.9 × 10-5
Rfx1p 87 23 7.08 3.2 6.0 × 10-7 7.7 × 10-5
Stp1p 91 23 7.35 3.1 1.1 × 10-6 1.4 × 10-4
Rtg3p 108 24 8.71 2.8 1.9 × 10-6 2.4 × 10-4
Swi4p 302 47 24.49 1.9 2.5 × 10-6 3.3 × 10-4
Rgt1p 44 14 3.54 4.0 2.9 × 10-6 3.7 × 10-4
Ino4p 333 50 26.94 1.9 3.1 × 10-6 4.0 × 10-4
Sut1p 34 12 2.72 4.4 4.1 × 10-6 5.3 × 10-4
Gat4p 64 18 5.17 3.5 4.5 × 10-6 5.8 × 10-4
Nrg1p 168 31 13.61 2.3 4.7 × 10-6 6.1 × 10-4
a) Number of genes associated to each factor, following YEASTRACT. Only genes used in the microarray analysis (3458) were considered.BMC Genomics 2008, 9:358 http://www.biomedcentral.com/1471-2164/9/358
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DNA Microarray Analysis
Microarrays used in this work were produced at the
Genomics Unit of the Scientific Park of Madrid (Spain).
They consist of 13,824 spots, each one corresponding to a
synthetic oligonucleotide (70-mer, Yeast Genome Oligo
Set, OPERON, Cologne, Germany) encompassing the
complete set of 6306 ORFs coded by the S. cerevisiae
genome. Each ORF was printed at least twice; 600 spots
were used as negative controls, either void or printed with
random oligonucleotides; a small subset of genes (ACT1,
Table 7: Transcription factors selectively enriched in daunorubicin-down regulated gene promoters
Factor Found/expected pa) Binding sequences CpG steps Characteristics/Function
Gis1p 4.76 1.9 × 10-14 TWAGGGAT, AGGGG JmjC domain-containing histone demethylase; transcription 
factor involved in the expression of genes during nutrient 
limitation; also involved in the negative regulation of DPP1 
and PHR1
Sut1p 4.41 5.3 × 10-4 CGCG * Transcription factor of the Zn [II]2Cys6 family involved in 
sterol uptake; involved in induction of hypoxic gene 
expression
Cst6p 4.27 5.1 × 10-13 TGACGTCA, TTACGTAA * Basic leucine zipper (bZIP) transcription factor of the ATF/
CREB family, activates transcription of genes involved in 
utilization of non-optimal carbon sources; involved in 
telomere maintenance
Pdr3p 4.26 3.1 × 10-10 TCCGCGGA * Transcriptional activator of the pleiotropic drug resistance 
network, regulates expression of ATP-binding cassette (ABC) 
transporters through binding to cis-acting sites known as 
PDREs (PDR responsive elements)
Rgt1p 3.95 3.7 × 10-4 CGGANNA * Glucose-responsive transcription factor that regulates 
expression of several glucose transporter (HXT) genes in 
response to glucose; binds to promoters and acts both as a 
transcriptional activator and repressor
Xbp1p 3.82 6.9 × 10-8 GCCTCGARMGA * Transcriptional repressor that binds to promoter sequences 
of the cyclin genes, CYS3, and SMF2; expression is induced by 
stress or starvation during mitosis, and late in meiosis; 
member of the Swi4p/Mbp1p family; potential Cdc28p 
substrate
Mig1p 3.51 1.4 × 10-5 W(4-5)GCGGGG * Transcription factor involved in glucose repression; sequence 
specific DNA binding protein containing two Cys2His2 zinc 
finger motifs; regulated by the SNF1 kinase and the GLC7 
phosphatase
Gat4p 3.48 5.8 × 10-4 GATA Protein containing GATA family zinc finger motifs
Ino2p 3.37 1.6 × 10-5 WYTTCAYRTGS * Component of the heteromeric Ino2p/Ino4p basic helix-loop-
helix transcription activator that binds inositol/choline-
responsive elements (ICREs), required for derepression of 
phospholipid biosynthetic genes in response to inositol 
depletion
Rfx1p 3.25 7.7 × 10-5 TCRYYRYRGCAAC * Protein involved in DNA damage and replication checkpoint 
pathway; recruits repressors Tup1p and Cyc8p to promoters 
of DNA damage-inducible genes; similar to a family of 
mammalian DNA binding RFX1-4 proteins
Gcr2p 3.17 3.6 × 10-5 CTTCC, CWTCC (Gcr1p) Transcriptional activator of genes involved in glycolysis; 
interacts and functions with the DNA binding protein Gcr1p
Stp1p 3.13 1.4 × 10-4 CGGCN(6)CGGC * Transcription factor, activated by proteolytic processing in 
response to signals from the SPS sensor system for external 
amino acids; activates transcription of amino acid permease 
genes and may have a role in tRNA processing
Stp2p 3.02 2.0 × 10-6 CGGGGTGN(7)CGCACCG * Transcription factor, activated by proteolytic processing in 
response to signals from the SPS sensor system for external 
amino acids; activates transcription of amino acid permease 
genes
Adr1p 3.01 4.6 × 10-8 TTGGRGN(6-38)CYCCAA Carbon source-responsive zinc-finger transcription factor, 
required for transcription of the glucose-repressed gene 
ADH2, of peroxisomal protein genes, and of genes required 
for ethanol, glycerol, and fatty acid utilization
a) Hypergeometric distribution with Bonferroni correctionBMC Genomics 2008, 9:358 http://www.biomedcentral.com/1471-2164/9/358
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HSP104, NUP159, NUP82, RPL32, RPS6B, SWI1, TDH1,
TDH2, TUB4 and UBI1) were printed between 6 and 12
times for testing reproducibility.
Fifteen μg of total RNA were used for cDNA synthesis and
labelling with Cy3-dUTP and Cy5-dUTP fluorescent
nucleotides, following indirect labelling protocol
(CyScribe post-labelling kit, GE-Healthcare, New York,
NY, USA). Labelling efficiency was evaluated by measur-
ing Cy3 or Cy5 absorbance in Nanodrop Spectrophotom-
eter. Microarray prehybridization was performed in 5×
SSC (SSC: 150 mM NaCl, 15 mM Na-citrate, pH 7.0),
0.1% SDS, 1%BSA at 42°C for 45 min. (Fluka, Sigma-
Aldrich, Buchs SG, Switzerland). Labelled cDNA was dried
in a vacuum trap and used as probe after resuspension in
110  μl of hybridization solution (50% Formamide,
5×SSC, 0.1% SDS, 100 μg/ml salmon sperm from Invitro-
gen, Carlsbad, CA, USA). Hybridization and washing were
performed in a Lucidea Slide Pro System (GE Healthcare,
Uppsala, Sweden). Arrays were scanned with a GenePix
4000B fluorescence scanner and analyzed by Genepix 5.0
Pro software (Axon Instruments, MDS Analytical Technol-
ogies, Toronto, Canada). Data was filtered according to
spot quality. Only those spots whose intensity was twice
background signal and, at least 75% of pixels had intensi-
ties above background plus two standard deviations were
selected for further calculations. In average, about 60 to
70% of spots in each array were considered suitable for
further analysis following these criteria.
Quantitative Real Time RT-PCR Assay
An aliquot of RNA preparations from untreated and
treated samples, used in the microarray experiments, was
saved for qRT-PCR follow-up studies. First strand cDNA
was synthesized from 2 μg of total DNAseI-treated RNA in
a 20 μl reaction volume using Omniscript RT Kit (Qiagen,
Valencia, CA, USA) following manufacture's instructions.
qRT-PCR reactions were performed by triplicate using the
ABI-PRISM 7000 Sequence Detection System (Applied
Biosystems, Foster City, CA, USA) using the SYBR Green
PCR Master Mix (Applied Biosystems). Gene-specific
primers (listed in Table 4) were designed using Primer
Express software (Applied Biosystems). Amplified frag-
ments were confirmed by sequencing in a 3730 DNA Ana-
lyzer (Applied Biosystems) and sequences were compared
with the published genomic data at SGD. Real time PCR
conditions included an initial denaturation step at 95°C
for 10 min, followed by 40 cycles of a two steps amplifi-
cation protocol: denaturation at 95°C for 15 s and anneal-
ing/extension at 60°C for 1 min. Relative expression
values of different genes were calculated following the
ΔΔCT method [31,32], using RPO21 as reference gene.
Table 8: Correlation coefficient and associated p values between 
daunorubicin-treated and Transcription-factor deleted strainsa)
Deletion strain r p (T-test) Bonferroni
Δsok2 0.428 3.1 × 10-19 3.1 × 10-17
Δadr1 0.427 3.8 × 10-19 3.8 × 10-17
Δcst6 0.344 1.5 × 10-12 1.5 × 10-10
Δpho4 0.256 2.1 × 10-7 2.1 × 10-5
Δste12 0.239 1.3 × 10-6 1.3 × 10-4
Δhap4 0.236 1.9 × 10-6 1.9 × 10-4
a) Only genes significantly altered by daunorubicin treatment were 
considered (n = 445).
Transcription ratios between daunorubicin-treated cells and three strains deleted for different transcription factors Figure 5
Transcription ratios between daunorubicin-treated cells and three strains deleted for different transcription 
factors. The X-axis corresponds to microarray data for cells treated with daunorubicin for four hours (treated vs. untreated, 
log2 values). The Y-axis corresponds to data from reference [17]. Only data for the 475 genes affected by daunorubicin were 
considered.BMC Genomics 2008, 9:358 http://www.biomedcentral.com/1471-2164/9/358
Page 14 of 16
(page number not for citation purposes)
Table 9: Genes and conditions used for the graph in Figure 6.
Gly genes rpg genes rpg genes Experiments/conditions
ADH1 RPL10 RPL6A DNA damagea Osmotic stressb Oxidative stressb
ADH2 RPL11A RPL6B DES460 + 0.02% MMS - 120 min 1M sorbitol - 120 min 1 mM Menadione (10 min)redo
ADH3 RPL11B RPL7A DES460 + 0.02% MMS - 15 min 1M sorbitol - 15 min 1 mM Menadione (105 min) redo
ADH5 RPL12A RPL7B DES460 + 0.02% MMS - 30 min 1M sorbitol - 30 min 1 mM Menadione (120 min)redo
CDC19 RPL12B RPL8A DES460 + 0.02% MMS - 5 min 1M sorbitol - 45 min 1 mM Menadione (160 min) redo
ENO1 RPL13A RPL8B DES460 + 0.02% MMS - 60 min 1M sorbitol - 5 min 1 mM Menadione (20 min) redo
ENO2 RPL13B RPL9A DES460 + 0.02% MMS - 90 min 1M sorbitol - 60 min 1 mM Menadione (30 min) redo
FBA1 RPL14B RPL9B DES460 + 0.2% MMS - 45 min 1M sorbitol - 90 min 1 mM Menadione (50 min)redo
GLK1 RPL15B RPS0A wt_plus_gamma_10_min Hypo-osmotic shock - 15 min 1 mM Menadione (80 min) redo
GPM1 RPL16A RPS0B wt_plus_gamma_120_min Hypo-osmotic shock - 30 min 1.5 mM diamide (10 min)
GPM2 RPL16B RPS10A wt_plus_gamma_20_min Hypo-osmotic shock - 45 min 1.5 mM diamide (20 min)
GPM3 RPL17A RPS10B wt_plus_gamma_30_min Hypo-osmotic shock - 5 min 1.5 mM diamide (30 min)
HXK1 RPL17B RPS11A wt_plus_gamma_45_min Hypo-osmotic shock - 60 min 1.5 mM diamide (40 min)
HXK2 RPL18A RPS11B wt_plus_gamma_5_min 1.5 mM diamide (5 min)
LAT1 RPL18B RPS12 wt_plus_gamma_60_min AA/N starvationb 1.5 mM diamide (50 min)
PDA1 RPL19A RPS13 wt_plus_gamma_90_min aa starv 0.5 h 1.5 mM diamide (60 min)
PDB1 RPL19B RPS14A aa starv 1 h 1.5 mM diamide (90 min)
PDC1 RPL1A RPS14B aa starv 2 h 1 mM Menadione (40 min) redo
PDC5 RPL1B RPS15 Temperatureb aa starv 4 h 2.5 mM DTT 005 min dtt-1
PDX1 RPL20A RPS16A 17 deg growth ct-1 aa starv 6 h 2.5 mM DTT 015 min dtt-1
PFK1 RPL20B RPS16B 21 deg growth ct-1 Nitrogen Depletion 1 d 2.5 mM DTT 030 min dtt-1
PFK2 RPL21A RPS17A 25 deg growth ct-1 Nitrogen Depletion 1 h 2.5 mM DTT 045 min dtt-1
PGI1 RPL21B RPS17B 29 deg growth ct-1 Nitrogen Depletion 12 h 2.5 mM DTT 060 min dtt-1
PGK1 RPL22A RPS18A 29C to 33C - 15 minutes Nitrogen Depletion 2 d 2.5 mM DTT 090 min dtt-1
PGM1 RPL22B RPS18B 29C to 33C - 30 minutes Nitrogen Depletion 2 h 2.5 mM DTT 120 min dtt-1
PGM2 RPL23A RPS19A 29C to 33C - 5 minutes Nitrogen Depletion 3 d 2.5 mM DTT 180 min dtt-1
STO1 RPL23B RPS19B 33C vs. 30C - 90 minutes Nitrogen Depletion 30 min. constant 0.32 mM H2O2 (10 min) redo
TDH1 RPL24A RPS1A 37 deg growth ct-1 Nitrogen Depletion 4 h constant 0.32 mM H2O2 (100 min) redo
TDH2 RPL24B RPS1B DBY7286 37 degree heat - 20 min Nitrogen Depletion 5 d constant 0.32 mM H2O2 (120 min) redo
TDH3 RPL25 RPS2 DBYmsn2/4 (real strain) + 37 degrees (20 
min)
Nitrogen Depletion 8 h constant 0.32 mM H2O2 (160 min) redo
TPI1 RPL26A RPS20 DBYmsn2-4- 37 degree heat - 20 min constant 0.32 mM H2O2 (20 min) redo
TYE7 RPL26B RPS21A Heat Shock 005 minutes hs-2 Stationary phaseb constant 0.32 mM H2O2 (30 min) redo
RPL27A RPS22A Heat Shock 015 minutes hs-2 YPD 1 d ypd-2 constant 0.32 mM H2O2 (40 min) rescan
RPL27B RPS22B Heat Shock 030inutes hs-2 YPD 10 h ypd-2 constant 0.32 mM H2O2 (50 min) redo
RPL28 RPS23A Heat Shock 05 minutes hs-1 YPD 12 h ypd-2 constant 0.32 mM H2O2 (60 min) redo
RPL2A RPS23B Heat Shock 060 minutes hs-2 YPD 2 d ypd-2 constant 0.32 mM H2O2 (80 min) redo
RPL3 RPS24A Heat Shock 10 minutes hs-1 YPD 2 h ypd-2 DBY7286 + 0.3 mM H2O2 (20 min)
RPL30 RPS24B Heat Shock 15 minutes hs-1 YPD 3 d ypd-2 DBYmsn2/4 (real strain) + 0.32 mM H2O2 
(20 min)
RPL31A RPS25A heat shock 17 to 37, 20 minutes YPD 4 h ypd-2 DBYmsn2msn4 (good strain) + 0.32 mM 
H2O2
RPL31B RPS25B Heat Shock 20 minutes hs-1 YPD 5 d ypd-2 dtt 000 min dtt-2
RPL32 RPS26A heat shock 21 to 37, 20 minutes YPD 6 h ypd-2 dtt 015 min dtt-2
RPL33A RPS26B heat shock 25 to 37, 20 minutes YPD 8 h ypd-2 dtt 030 min dtt-2
RPL33B RPS27A heat shock 29 to 37, 20 minutes YPD stationary phase 1 d ypd-1 dtt 060 min dtt-2
RPL34B RPS27B Heat Shock 30 minutes hs-1 YPD stationary phase 12 h ypd-1 dtt 120 min dtt-2
RPL35A RPS28A heat shock 33 to 37, 20 minutes YPD stationary phase 13 d ypd-1 dtt 240 min dtt-2
RPL35B RPS28B Heat Shock 40 minutes hs-1 YPD stationary phase 2 d ypd-1 dtt 480 min dtt-2
RPL36A RPS29A Heat Shock 60 minutes hs-1 YPD stationary phase 2 h ypd-1
RPL37A RPS29B Heat Shock 80 minutes hs-1 YPD stationary phase 22 d ypd-1
RPL37B RPS3 steady state 15 dec C ct-2 YPD stationary phase 28 d ypd-1
RPL38 RPS30A steady state 17 dec C ct-2 YPD stationary phase 3 d ypd-1
RPL39 RPS30B steady state 21 dec C ct-2 YPD stationary phase 4 h ypd-1
RPL40A RPS31 steady state 25 dec C ct-2 YPD stationary phase 5 d ypd-1
RPL40B RPS4A steady state 29 dec C ct-2 YPD stationary phase 7 d ypd-1
RPL41A RPS4B steady state 33 dec C ct-2 YPD stationary phase 8 h ypd-1
RPL42A RPS6A steady state 36 dec C ct-2
RPL42B RPS6B steady state 36 dec C ct-2 
(repeat hyb)
RPL43A RPS7A
RPL43B RPS7B
RPL4A RPS8A
RPL4B RPS8B
RPL5 RPS9A
RPS9B
a) Data from reference [21]
b) Data from reference [22]BMC Genomics 2008, 9:358 http://www.biomedcentral.com/1471-2164/9/358
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Clustering and statistical analysis
Our experimental design allowed to obtain up to 6 deter-
minations for each gene and condition: three biological
replicates per condition, two replicated spots for each
gene in the array. Statistical analyses only considered
genes for which a minimum of nine (out of 18) data val-
ues passed the microarray quality standards (3458 genes).
Data were calculated as binary logarithms (log2) of fluo-
rescence ratios (treated versus untreated samples). Signif-
icant changes on expression values between the starting
point (time 0) and samples taken at 1 and 4 hours of dau-
norubicin treatment were determined by the Student's T-
test. The whole dataset, combining data from the three
time points, was analyzed with the TIGR MeV program
[33]. Data were normalised by experiments and clustered
by hierarchical clustering (Euclidean distance), treating
duplicated spots as independent data series. Genes show-
ing significant variations between time points were iden-
tified by ANOVA with the Bonferroni correction (p <
0.05). These genes were grouped by their expression pat-
terns in a two-dimensional map grid by SOM (Self-Organ-
izing Maps) [34], to generate hypotheses on the
relationships and the function of genes. Classification of
genes by gene ontology (GO) in biological process catego-
ries [35] was performed in the SDG page. Documented
regulators of both affected and non-affected genes were
retrieved from YEASTRACT [16]. Statistical analyses on
the frequency of regulated genes in different subsets of
data were performed using hypergeometric distribution
tests with the Bonferroni correction (see SGD page, and
http://mathworld.wolfram.com/HypergeometricDistri
bution.html)
Authors' contributions
MR: Growth effects, microarray analysis, qRT-PCR. MC:
qRT-PCR analysis, technical assistance. JP & BP: co-direc-
tion, data mining and analysis, preparation and writing of
the manuscript. All co-authors read and approved the
manuscript.
Acknowledgements
This work has been supported by the Spanish Ministry for Education and 
Science (MEC, grants BIO2005-00840, BFU2007-60998/BMC and 
AGL2000-0133-P4-03). The contribution of the Centre de Referència en 
Biotecnologia de la Generalitat de Catalunya is also acknowledged.
References
1. Gewirtz DA: A critical evaluation of the mechanisms of action
proposed for the antitumor effects of the anthracycline anti-
biotics adriamycin and daunorubicin.  Biochem Pharmacol 1999,
57:727-741.
2. Roninson IB, Broude EV, Chang BD: If not apoptosis, then what?
Treatment-induced senescence and mitotic catastrophe in
tumor cells.  Drug Resistance Updates 2001, 4(5):303-313.
3. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L: Anthracy-
clines: molecular advances and pharmacologic develop-
ments in antitumor activity and cardiotoxicity.  Pharmacol Rev
2004, 56(2):185-229.
4. Chaires JB: Molecular recognition of DNA by daunorubicin.  In
Advances in DNA sequence specific agents Volume 2. Edited by: Hurley L,
Chaires JB. Greenwich, CT: JAI Press Inc; 1996:141-167. 
5. Belloc F, Lacombe F, Dumain P, Lopez F, Bernard P, Boisseau MR,
Reifers J: Intercalation of anthracyclines into living cell DNA
analyzed by flow cytometry.  Cytometry 1992, 13:880-885.
6. Portugal J, Martín B, Vaquero A, Ferrer N, Villamarín S, Priebe W:
Analysis of the effects of daunorubicin and WP631 on tran-
scription.  Curr Med Chem 2001, 8:1-8.
Differential expression for glycolytic genes (gly) and ribos- omal protein genes (rpg) in yeast cells subjected to different  treatments Figure 6
Differential expression for glycolytic genes (gly) and 
ribosomal protein genes (rpg) in yeast cells subjected 
to different treatments. Fold induction or repression val-
ues were calculated for 32 glycolytic genes and 123 ribos-
omal protein genes for each of the 146 stress conditions, 
plus the two daunorubicin treatments. The X-axis values cor-
respond to ratios between the average of fold induction/
repression for glycolitic and ribosomal protein genes for in 
each experiment; Y-axis indicates the probability of both sets 
of genes being equally affected by each treatment. Note the 
reverse scale of the Y-axis. Each dot represent a single stress 
dataset for a particular stress condition; they are grouped in 
several categories: Daunorubicin treatment (DNR, 1 h and 4 
h, red squares), DNA damaging agents (DD, 15 conditions, 
blue diamonds), osmotic stress (OS, 12 conditions, green tri-
angles), oxidative stress (Ox, 45 conditions, yellow diamond), 
temperature stress (T, 37 conditions, orange circle), amino 
acid and nitrogen starvation (N, 15 conditions, dark brown 
circle) and maintenance in stationary phase for long periods 
of time (22 conditions, red triangles). Two vertical, discontin-
uous lines indicate 2-fold induction or repression; note that 
ratio values are expressed as log2 transformants. Except for 
daunorubicin-treatment, all data are from references [21,22]. 
Genes and conditions analysed are listed in Table 9.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Genomics 2008, 9:358 http://www.biomedcentral.com/1471-2164/9/358
Page 16 of 16
(page number not for citation purposes)
7. Mansilla S, Piña B, Portugal J: Daunorubicin-induced variations in
gene transcription: Commitment to proliferation arrest,
senescence and apoptosis.  Biochem J 2003, 372(3):703-711.
8. Martín B, Vaquero A, Priebe W, Portugal J: Bisanthracycline
WP631 inhibits basal and Sp1-activated transcription initia-
tion in vitro.  Nucleic Acids Res 1999, 27:3402-3409.
9. Dal Ben D, Palumbo M, Zagotto G, Capranico G, Moro S: DNA
topoisomerase II structures and anthracycline activity:
insights into ternary complex formation.  Curr Pharm Des 2007,
13(27):2766-2780.
10. Chaires JB, Herrera JE, Waring MJ: Preferential binding of daun-
omycin to 5'ATCG and 5'ATGC sequences revealed by foot-
printing titration experiments.  Biochemistry 1990,
29(26):6145-6153.
11. Leng FF, Leno GH: Daunomycin disrupts nuclear assembly and
the coordinate initiation of DNA replication in Xenopus egg
extracts.  J Cell Biochem 1997, 64:476-491.
12. Marín S, Mansilla S, García-Reyero N, Rojas M, Portugal J, Piña B: Pro-
moter-specific inhibition of transcription by daunorubicin in
Saccharomyces cerevisiae.  Biochem J 2002, 368(1):131-136.
13. Perego P, Jimenez GS, Gatti L, Howell SB, Zunino F: Yeast mutants
as a model system for identification of determinants of
chemosensitivity.  Pharmacol Rev 2000, 52:477-492.
14. Nitiss J, Wang JC: DNA topoisomerase-targeting antitumor
drugs can be studied in yeast.  Proc Natl Acad Sci USA 1988,
85:7501-7505.
15. Liang SD, Marmorstein R, Harrison SC, Ptashne M: DNA sequence
preferences of GAL4 and PPR1: How a subset of Zn2Cys6
binuclear cluster proteins recognizes DNA.  Mol Cell Biol 1996,
16:3773-3780.
16. Teixeira MC, Monteiro P, Jain P, Tenreiro S, Fernandes AR, Mira NP,
Alenquer M, Freitas AT, Oliveira AL, Sa-Correia I: The YEAS-
TRACT database: a tool for the analysis of transcription reg-
ulatory associations in Saccharomyces cerevisiae.  Nucleic Acids
Res 2006:D446-451.
17. Chua G, Morris QD, Sopko R, Robinson MD, Ryan O, Chan ET, Frey
BJ, Andrews BJ, Boone C, Hughes TR: Identifying transcription
factor functions and targets by phenotypic activation.  Proc
Natl Acad Sci USA 2006, 103(32):12045-12050.
18. Simon JA, Bedalov A: Yeast as a model system for anticancer
drug discovery.  Nat Rev Cancer 2004, 4(6):481-492.
19. Benton MG, Somasundaram S, Glasner JD, Palecek SP: Analyzing
the dose-dependence of the Saccharomyces cerevisiae global
transcriptional response to methyl methanesulfonate and
ionizing radiation.  BMC Genomics 2006, 7:305.
20. Menacho-Marquez M, Murguia JR: Yeast on drugs: Saccharomy-
ces cerevisiae as a tool for anticancer drug research.  Clin
Transl Oncol 2007, 9(4):221-228.
21. Gasch AP, Spellman PT, Kao CM, Carmel-Harel O, Eisen MB, Storz
G, Botstein D, Brown PO: Genomic expression programs in the
response of yeast cells to environmental changes.  Molecular
Biology of the Cell 2000, 11(12):4241-4257.
22. Gasch AP, Huang M, Metzner S, Botstein D, Elledge SJ, Brown PO:
Genomic expression responses to DNA-damaging agents
and the regulatory role of the yeast ATR Homolog Mec1p.
Molecular Biology of the Cell 2001, 12(10):2987-3003.
23. Gancedo JM: Yeast carbon catabolite repression.  Microbiol Mol
Biol Rev 1998, 62(2):334-361.
24. García-Gimeno M, Struhl K: Aca1 and Aca2, ATF/CREB activa-
tors in Saccharomyces cerevisiae, are important for carbon
source utilization but not the response to stress.  Mol Cell Biol
2000, 20:4340-4349.
25. Ward MP, Gimeno CJ, Fink GR, Garrett S: SOK2 may regulate
cyclic AMP-dependent protein kinase-stimulated growth
and pseudohyphal development by repressing transcription.
Mol Cell Biol 1995, 15(12):6854-6863.
26. Harbison CT, Gordon DB, Lee TI, Rinaldi NJ, Macisaac KD, Danford
TW, Hannett NM, Tagne JB, Reynolds DB, Yoo J, Jennings EG, Zei-
tlinger J, Pokholok DK, Kellis M, Rolfe PA, Takusagawa KT, Lander ES,
Gifford DK, Fraenkel E, Young RA: Transcriptional regulatory
code of a eukaryotic genome.  Nature 2004, 431(7004):99-104.
27. Gniazdowski M, Denny WA, Nelson SM, Czyz M: Effects of anti-
cancer drugs on transcription factor-DNA interactions.
Expert Opin Ther Targets 2005, 9(3):471-489.
28. Mansilla S, Portugal J: Sp1 transcription factor as a target for
anthracyclines: Effects on gene transcription.  Biochimie 2008,
90:976-987.
29. Pelicano H, Martin DS, Xu RH, Huang P: Glycolysis inhibition for
anticancer treatment.  Oncogene 2006, 25(34):4633-4646.
30. Cao X, Fang L, Gibbs S, Huang Y, Dai Z, Wen P, Zheng X, Sadee W,
Sun D: Glucose uptake inhibitor sensitizes cancer cells to dau-
norubicin and overcomes drug resistance in hypoxia.  Cancer
Chemother Pharmacol 2007, 59(4):495-505.
31. Livak KJ, Schmittgen TD: Analysis of relative gene expression
data using real-time quantitative PCR and the 2(-Delta Delta
C(T)) Method.  Methods 2001, 25(4):402-408.
32. Pfaffl M: A new mathematical model for relative quantifica-
tion in real-time RT-PCR.  Nucl Acids Res 2001, 29:e45.
33. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, Braisted J,
Klapa M, Currier T, Thiagarajan M, Sturn A, Snuffin M, Rezantsev A,
Popov D, Ryltsov A, Kostukovich E, Borisovsky I, Liu Z, Vinsavich A,
Trush V, Quackenbush J: TM4: a free, open-source system for
microarray data management and analysis.  Biotechniques 2003,
34(2):374-378.
34. Nikkila J, Toronen P, Kaski S, Venna J, Castren E, Wong G: Analysis
and visualization of gene expression data using self-organiz-
ing maps.  Neural Netw 2002, 15(8–9):953-966.
35. Dwight SS, Harris MA, Dolinski K, Ball CA, Binkley G, Christie KR,
Fisk DG, Issel-Tarver L, Schroeder M, Sherlock G, Sethuraman A,
Weng S, Botstein D, Cherry JM: Saccharomyces Genome Data-
base (SGD) provides secondary gene annotation using the
Gene Ontology (GO).  Nucleic Acids Res 2002, 30(1):69-72.